MTDH and EphA7 are markers for metastasis and poor prognosis of gallbladder adenocarcinoma

Diagnostic Cytopathology

Volumn 41, Issue 3, 2013, Pages 199-205

  Liu, Dong Cai ^a   Yang, Zhu Lin ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

chronic cholecystitis; EphA7; gallbladder cancer; gallbladder polyp; MTDH

Indexed keywords

ERYTHROPOIETIN PRODUCING HEPATOMA AMPLIFIED SEQUENCE RECEPTOR A7; METADHERIN; PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CELL DIFFERENTIATION; CHRONIC CHOLECYSTITIS; CYTOPATHOLOGY; DISEASE ASSOCIATION; FEMALE; GALLBLADDER ADENOCARCINOMA; GALLBLADDER CANCER; GALLBLADDER EPITHELIUM; GALLSTONE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADICAL RESECTION;

ADENOCARCINOMA; ADULT; AGED; CELL ADHESION MOLECULES; CHINA; FEMALE; GALLBLADDER NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; RECEPTOR, EPHA7; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84874091389     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.21821     Document Type: Article

References (34)

1. Iiizumi M, Liu W, Pai SK, Furuta E, Watabe K,. Drug development against metastasis-related genes and their pathways: A rationale for cancer therapy. Biochim Biophys Acta 2008; 1786: 87-104.
2. Chambers AF, Groom AC, MacDonald IC,. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2: 563-572.
3. Brown DM, Ruoslahti E,. Metadherin, a cell surface protein in breast tumors that mediates lung metastasis. Cancer Cell 2004; 5: 365-374.
4. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
5. Wistuba II, Albores-Saavedra J,. Genetic abnormalities involved in the pathogenesis of gallbladder carcinoma. J Hepatobiliary Pancreat Surg 1999; 6: 237-244.
6. Jayaraman S, Jarnagin WR,. Management of gallbladder cancer. Gastroenterol Clin North Am 2010; 39: 331-342.
7. Hsing AW, Gao WT, Han TQ, et al. Gallstones and the risk of biliary tract cancer: A population-based study in China. Br J Cancer 2007; 97: 1577-1582.
8. Hawkins WG, DeMatteo RP, Jarnagin WR, Ben-Porat L, Blumgart LH, Fong Y,. Jaundice predicts advanced disease and early mortality in patients with gallbladder cancer. Ann Surg Oncol 2004; 11: 310-315.
9. Kwong LN, Chin L,. 2009. The metastasis problem gets stickier. Cancer Cell 15: 1-2.
10. Emdad L, Sarkar D, Su ZZ, et al. Astrocyte elevated gene-1: Recent insights into a novel gene involved in tumor progression, metastasis and neurodegeneration. Pharmacol Ther 2007; 114: 155-170.
11. Hu G, Wei Y, Kang Y,. The multifaceted role of MTDH/AEG-1 in cancer progression. Clin Cancer Res 2009; 15: 5615-5620.
12. Hu G, Chong RA, Yang Q, et al. MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell 2009; 15: 9-20.
13. Kikuno N, Shiina H, Urakami S, et al. Knockdown of astrocyte-elevated gene-1 inhibits prostate cancer progression through upregulation of FOXO3a activity. Oncogene 2007; 26: 7647-7655.
14. Yu C, Chen K, Zheng H, et al. Overexpression of astrocyte elevated gene-1 (AEG-1) is associated with esophageal squamous cell carcinoma (ESCC) progression and pathogenesis. Carcinogenesis 2009; 30: 894-901.
15. Wei Y, Hu G, Kang Y,. Metadherin as a link between metastasis and chemoresistance. Cell Cycle 2009; 8: 2132-2133.
16. Su P, Zhang Q,. Immunohistochemical analysis of metadherin in proliferative and cancerous breast tissue. Diagn Pathol 2010; 5: 38.
17. Giaginis C, Zira A, Katsargyris A, Klonaris C, Theocharis S,. Clinical implication of plasma neutrophil gelatinase-associated lipocalin (NGAL) concentrations in patients with advanced carotid atherosclerosis. Clin Chem Lab Med 2010; 48: 1035-1041.
18. Brückner K, Klein R,. Signaling by Eph receptors and their ephrin ligands. Curr Opin Neurobiol 1998; 8: 375-382.
19. Pasquale EB,. Eph-ephrin bidirectional signaling in physiology and disease. Cell 2008; 133: 38-52.
20. Surawska H, Ma PC, Salgia R,. The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev 2004; 15: 419-433.
21. Nakanishi H, Nakamura T, Canaani E, Croce CM,. ALL1 fusion proteins induce deregulation of EphA7 and ERK phosphorylation in human acute leukemias. Proc Natl Acad Sci USA 2007; 104: 14442-14447.
22. Brantley-Sieders D, Schmidt S, Parker M, Chen J,. Eph receptor tyrosine kinases in tumor and tumor microenvironment. Curr Pharm Des 2004; 10: 3431-3442.
23. Héroult M, Schaffner F, Augustin HG,. Eph receptor and ephrin ligand-mediated interactions during angiogenesis and tumor progression. Exp Cell Res 2006; 312: 642-650.
24. Wang J, Kataoka H, Suzuki M, et al. Downregulation of EphA7 by hypermethylation in colorectal cancer. Oncogene 2005; 24: 5637-5647.
25. Wang J, Li G, Ma H, et al. Differential expression of EphA7 receptor tyrosine kinase in gastric carcinoma. Hum Pathol 2007; 38: 1649-1656.
26. Wang LF, Fokas E, Juricko J, et al. Increased expression of EphA7 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients. BMC Cancer 2008; 879.
27. Tsuboi M, Mori H, Bunai T, et al. Secreted form of EphA7 in lung cancer. Int J Oncol 2010; 36: 635-640.
28. Giaqinis C, Tsourouflis G, Zizi-serbetzoglou A, et al. Clinical significance of ephrin(eph)-A1,-A2,-a4,-a5 and -a7 receptors in pancreatic ductal adenocarcinoma. Pathol Oncol Res 2010; 16: 267-276.
29. Yamagiwa H, Tomiyama H, Yoshimura H,. Histogenesis of carcinoma of gallbladder. Histolohical study of serial sections of 1000 cases of resected gallbladder. Rinsho Byori 1986; 34; 475-480.
30. Dowling GP, Kelly JK,. The histogenesis of adenocarcinoma of the gallbladder. Cancer 1986; 58; 1702-1708.
31. Chang HJ, Yoo BC, Kim SW, Lee BL, Kim WH,. Significance of PML and p53 protein as molecular prognostic markers of gallbladder carcinomas. Pathol Oncol Res 2007; 13; 326-335
32. Németh Z, Szász AM, Somorácz A, et al. Zonula Occludens-1, Occludin, and E-cadherin Protein Expression in Biliary Tract cancers. Pathol Oncol Res 2009; 15; 533-539
33. Li Q, Yang Z,. Expression of phospho-ERK1/2 and PI3-K in benign and malignant gallbladder lesions and its clinical and pathological correlations. J Exp Clin Cancer Res 2009; 28; 65-67.
34. Gakiopoulou H, Korkolopoulou P, Levidou G, et al. Minichromosome maintenance 2 and 5 in nonbenign epithelial ovarian tumours: Relationship with cell cycle regulators and prognostic implications. Br J Cancer 2007; 97; 1124-1134.